Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
01 2021
Historique:
received: 19 06 2020
revised: 09 10 2020
accepted: 10 10 2020
pubmed: 14 10 2020
medline: 1 10 2021
entrez: 13 10 2020
Statut: ppublish

Résumé

High-throughput sequencing analysis represented both a medical diagnosis and technological revolution. Gene panel analysis is now routinely performed in the exploration of hereditary predisposition to cancer, which is becoming increasingly heterogeneous, both clinically and molecularly. We present 1530 patients with suspicion of hereditary predisposition to cancer, for which two types of analyses were performed: a) oriented according to the clinical presentation (n = 417), or b) extended to genes involved in hereditary predisposition to adult cancer (n = 1113). Extended panel analysis had a higher detection rate compared to oriented analysis in hereditary predisposition to breast / ovarian cancer (P < .001) and in digestive cancers (P < .094) (respectively 15% vs 5% and 19.3%, vs 12.5%). This higher detection is explained by the inclusion of moderate penetrance genes, as well as the identification of incident mutations and double mutations. Our study underscores the utility of proposing extended gene panel analysis to patients with suspicion of hereditary predisposition to adult cancer.

Identifiants

pubmed: 33047316
doi: 10.1111/cge.13864
pmc: PMC7821123
doi:

Substances chimiques

Neoplasm Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-175

Informations de copyright

© 2020 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.

Références

Adv Chronic Kidney Dis. 2014 Jan;21(1):81-90
pubmed: 24359990
Orphanet J Rare Dis. 2016 Nov 25;11(1):159
pubmed: 27884168
Clin Genet. 2015 Jun;87(6):582-7
pubmed: 24814045
Int J Cancer. 2008 Feb 15;122(4):802-6
pubmed: 17957789
J Natl Compr Canc Netw. 2017 Dec;15(12):1465-1475
pubmed: 29223984
Histopathology. 2018 Jan;72(1):97-105
pubmed: 29239044
Lancet Oncol. 2015 Feb;16(2):e60-70
pubmed: 25638682
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Br J Cancer. 2009 May 5;100(9):1508-12
pubmed: 19401704
Eur J Med Genet. 2016 Mar;59(3):126-32
pubmed: 26826318
Fam Cancer. 2019 Apr;18(2):273-280
pubmed: 30607672
World J Gastroenterol. 2017 Feb 14;23(6):935-948
pubmed: 28246467
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
Int J Cancer. 2015 Aug 1;137(3):548-52
pubmed: 25583358
Eur J Hum Genet. 2018 Nov;26(11):1597-1602
pubmed: 29967336
Genet Med. 2014 Jan;16(1):101-16
pubmed: 24310308
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
J Med Genet. 2014 Feb;51(2):108-13
pubmed: 24277755
Ann Dermatol Venereol. 2015 Jan;142(1):26-36
pubmed: 25600792
Genet Med. 2016 Aug;18(8):823-32
pubmed: 26681312
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Genet. 2021 Jan;99(1):166-175
pubmed: 33047316
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Breast Cancer Res Treat. 2010 Jan;119(2):443-52
pubmed: 19404735
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Breast Cancer Res. 2011;13(6):R119
pubmed: 22114986
Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4
pubmed: 21908500
J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189
pubmed: 30380096
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
Front Genet. 2018 Aug 31;9:353
pubmed: 30233642
Semin Oncol. 2016 Oct;43(5):566-574
pubmed: 27899189
Lancet. 2001 Oct 27;358(9291):1389-99
pubmed: 11705483
Genet Med. 2020 Feb;22(2):407-415
pubmed: 31406321
Clin Genet. 2020 Apr;97(4):668-669
pubmed: 31875949
Lancet Oncol. 2011 May;12(5):477-88
pubmed: 21514219
Int J Mol Sci. 2017 Jan 31;18(2):
pubmed: 28146134
Transl Gastroenterol Hepatol. 2018 Jan 09;3:2
pubmed: 29441367
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Int J Surg. 2017 May;41 Suppl 1:S2-S6
pubmed: 28506408
Cancer Lett. 2015 Dec 28;369(2):274-88
pubmed: 26427841
J Mol Diagn. 2019 Jul;21(4):646-657
pubmed: 31201024
Clin Gastroenterol Hepatol. 2017 Jun;15(6):809-819
pubmed: 27712984
Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):861-875
pubmed: 30665551
Eur J Hum Genet. 2009 Nov;17(11):1495-500
pubmed: 19367317
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Eur J Hum Genet. 2014 Aug;22(8):979-87
pubmed: 24301060
Endocr Rev. 2013 Apr;34(2):239-77
pubmed: 23371967
Cancer Discov. 2012 Jan;2(1):41-6
pubmed: 22585167
J Pediatr Genet. 2016 Jun;5(2):98-104
pubmed: 27617150
Gastroenterology. 2014 May;146(5):1208-11.e1-5
pubmed: 24444654
Clin Cancer Res. 2017 Jun 1;23(11):e23-e31
pubmed: 28572264

Auteurs

Mathias Cavaillé (M)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Nancy Uhrhammer (N)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Maud Privat (M)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Flora Ponelle-Chachuat (F)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Mathilde Gay-Bellile (M)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Mathis Lepage (M)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.

Sandrine Viala (S)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Yannick Bidet (Y)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Yves-Jean Bignon (YJ)

Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies, Clermont Ferrand, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH